-
公开(公告)号:EP4381513A1
公开(公告)日:2024-06-12
申请号:EP22761187.8
申请日:2022-08-04
申请人: Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts , Universität Heidelberg , Oxford Nanopore Technologies PLC
-
公开(公告)号:EP3746791B1
公开(公告)日:2024-03-06
申请号:EP19705289.7
申请日:2019-01-25
发明人: BUND, Timo , ZUR HAUSEN, Harald , DE VILLIERS, Ethel-Michele , TESSMER, Claudia , HEIKENWÄLDER, Mathias , WEBER, Achim , BURK-KÖRNER, Amelie
IPC分类号: G01N33/574
-
公开(公告)号:EP3856928B1
公开(公告)日:2022-11-09
申请号:EP19769176.9
申请日:2019-09-19
发明人: CATHOMEN, Toni , TURCHIANO, Giandomenico , BLATTNER, Georges , MONACO, Gianni , BÖRRIES, Melanie , ANDRIEUX, Geoffroy
IPC分类号: C12Q1/6848 , C12Q1/6869
-
公开(公告)号:EP3468621B1
公开(公告)日:2022-09-21
申请号:EP17730112.4
申请日:2017-06-08
发明人: BUJUPI, Fatmire , KRAMMER, Peter , WEYD, Heiko
-
公开(公告)号:EP3525886B8
公开(公告)日:2022-06-29
申请号:EP17784280.4
申请日:2017-10-13
IPC分类号: A61K47/69 , A61K31/724 , A61P35/00
-
公开(公告)号:EP3319945B1
公开(公告)日:2021-04-28
申请号:EP16733990.2
申请日:2016-07-04
IPC分类号: C07D235/08 , A61K31/4184 , A61K31/427 , C07D235/18 , C07D403/06 , C07D417/06 , A61P35/00
-
公开(公告)号:EP3350219B1
公开(公告)日:2020-08-26
申请号:EP16763839.4
申请日:2016-09-13
-
公开(公告)号:EP3693396A2
公开(公告)日:2020-08-12
申请号:EP20162696.7
申请日:2017-01-16
申请人: Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts , Eberhard Karls Universität Tübingen
摘要: The present invention provides a novel PSMA binding antibody termed 10B3 and pharmaceutical and diagnostic uses of the antibody 10B3. The PSMA antibody 10B3 does not cross-compete with the state of the art PMSA binding antibody J591 and has a reduced induction of antigen shift compared to J591 and a unique reactivity with squamous cell carcinoma (SCC) cells of different origin.
-
公开(公告)号:EP3063276B1
公开(公告)日:2020-07-15
申请号:EP14793065.5
申请日:2014-10-28
申请人: Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts , Ruprecht-Karls-Universität Heidelberg
IPC分类号: C12N15/113 , A61K31/7088 , A61P3/10
-
公开(公告)号:EP3590935A1
公开(公告)日:2020-01-08
申请号:EP18182128.1
申请日:2018-07-06
IPC分类号: C07D403/06 , A61K31/497 , A61P35/00
摘要: The present invention pertains to fused imidazolium derivatives, in particular 11-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho(2,3-d)imidazolium bromide for use in the treatment of colorectal cancer (CRC). The invention provides the therapeutic application of such compounds in a patient subgroup of CRC, which is characterized by a consensus molecular subtype (CMS) 1.
-
-
-
-
-
-
-
-
-